-
Multiple Sclerosis - Relapsing Forms
- Interferon has the longest use in MS than any of the other immunomodulators
-
Interferon is an endogenous Cytokine (integral to inflammatory and immune responses)
- Released from Lymphocytes, Dendritic Cells, Macrophages, fibroblasts, Natural Killer Cells and T Cells
-
Interferon is subdivided into three main types (alpha, beta, gamma)
- Alpha and beta Interferon both have Antiviral activity
- Synthesized alpha Interferon has primarily been used for Viral Hepatitis B and C infection, as well as cancer
- Synthesized beta Interferon has primarily been used to treat Multiple Sclerosis
- Interferon Beta is a type 1 Interferon, a Cytokine produced by fibroblasts
- Released in response to viral contact or DS-DNA
- Has Antiviral, antiproliferative and immunomodulator activity
- Interferon Beta-1A
- Avonex 30 mcg vials or prefilled syringes
- Rebif Titration Kits, and 22 and 44 mcg prefilled syringes and autoinjectors
- Peginterferon Beta-1A
- Plegridy Starter Pack and 125 mcg pens and prefilled syringes
- Avonex
- Target Dose: 30 mcg IM once weekly
- Start: 7.5 mcg IM weekly and increase dose by 7.5 mcg each week until at 30 mcg dose
- Titration allows for lower risk of flu-like symptoms
- Rebif
- Choose between 2 target doses
- Target 22 mcg SC three times weekly (same days each week, each dose 48 hours apart)
- Start 4.4 mcg SQ three times weekly for 2 weeks
- Next 11 mcg SQ three times weekly for 2 weeks,
- Next 22 mcg SQ three times weekly
- Target 44 mcg SC three times weekly (same days each week, each dose 48 hours apart)
- Start 8.8 mcg SQ three times weekly for 2 weeks
- Next 22 mcg SQ three times weekly for 2 weeks,
- Next 44 mcg SQ three times weekly
- Plegridy (Peginterferon Beta-1A)
- Day1: Start 63 mcg SQ
- Day 15: Increase to 94 mcg SQ
- Day 29: Increase to 125 mcg SQ
- Next: Continue 125 mcg SQ every 14 days
- Pretreat with Analgesics and Antihistamines to reduce flu-like reactions
- Increased drug levels and adverse reactions with renal Impairment
- Allergic Reactions (including Anaphylaxis)
- Local injection site inflammation
- Influenza-like symptoms (decreases after first 3 months)
- Mental health adverse effects
- Exacerbation of depressed mood (including increased Suicidality)
- Psychosis
- Hematologic Effects
- Hepatotoxicity
- Increased liver transaminases
- Risk of liver failure
- Avoid with other Hepatotoxins
- Monitor Liver Function Tests
- Pulmonary Arterial Hypertension
- Congestive Heart Failure
- Autoimmune disorders
- Seizures
- Pregnancy Category C
- Unknown Safety in Lactation
- Decreases Multiple Sclerosis exacerbation frequency
- Decreased risk of Disability progression
- Decreased MS related CNS Lesions
- Avonex (DailyMed)
- Rebif (DailyMed)
- Plegridy (DailyMed)